Alzheimer’s Community Prepares To Challenge CMS PET Proposal
This article was originally published in The Gray Sheet
Executive Summary
Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.